Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.21.1
Revenue Recognition - Narrative (Details)
$ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
segment
Mar. 31, 2020
USD ($)
Revenue from Contract with Customer [Abstract]    
Number of operating segments | segment 2  
Increase in Pharma contract assets $ 0.4  
Pharma contract asset, increase (as a percent) 23.00%  
Pharma contract liability, revenue recognized $ 2.7 $ 1.2
Amortization of contract commissions $ 0.2 $ 0.2